RNS Number : 4259U
ValiRx PLC
07 August 2025

7 August 2025

ValiRx PLC
("ValiRx" or the "Company")

ValiRx Awarded Grant from Open University

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea is pleased to confirm ithas been awarded a Knowledge Transfer Voucher ("KTV") to partner with The Open University ("OU"). This funding will be used to perform advanced imaging-based analysis of Inaphaea biolab's patient derived cell models. The project, which will run from 1st August 2025 to 30th September 2026, will utilise The Open University's expertise in biophysical and machine learning approaches for predicting self-organisation in tissues to build algorithms to assess drug responses in tumour spheroids. The three primary aims of the program are to carry out confocal microscopy of tumoroids provided by Inaphaea; to validate the use of the OU developed *contractile network dipole orientation* ("CONDOR") simulations to model these tumoroids and to strengthen links with Inaphaea for future grant applications.

Mark Eccleston, CEO of ValiRx commented*"We are grateful to The Open University for its continued support across multiple ValiRx companies as we work with leading academic experts to advance our technical capabilities around advanced PDC models and cell-based testing. This is the third award we have received and is very timely given recent updates to the FDA Modernization Act 2.0, which expands regulatory safety and efficacy testing options to include 3D cell cultures as a viable alternative to animal testing. We have built multiple partnerships to expand and develop our capabilities in this area to deliver better products and services through Inaphaea and progress assets faster and further down the pipeline with in-house resources, ultimately leading to better therapeutic candidates from our various SPVs."*

Jim Hague,Senior Lecturer at the Faculty of Science, Technology, Engineering & Mathematics, The Open University commented*"In partnership with Inaphaea, we want to improve spheroid use as models for drug-development, with a focus on treatments for major cancers (an area of significant interest for our partner, especially triple-negative breast, colorectal and prostate cancers).Our biophysical and machine learning solutions allow us to obtain key additional information about spheroid structure and cell organisation, vital to assess the health of the spheroid tissue. Therefore, addressing an unmet need for analytic tools to understand how accurately spheroid responses to drug candidates represent real tissues."*

The Directors of the Company take responsibility for this announcement.

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here:https://valirx.com/s/cc8ef3

For more information, please contact:

Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub	https://valirx.com/link/PljYke
ValiRx plc Dr Mark Eccleston, CEO	**Tel: +44 115 784 0026** www.valirx.com Mark.Eccleston@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti	**Tel: +44 (0) 20 7213 0880**

Shard Capital Partners LLP (Sole Broker) Damon Heath	**Tel: +44 (0) 20 7186 9000**
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director	**+44 (0) 115 787 0206** www.vformation.biz lucy@vformation.biz sue@vformation.biz

Subscribe to our news alert service:https://valirx.com/s/f298d1

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit:www.valirx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUBSKRVKUWRRR